Hims & Hers Closes Up 10% on Peptide Rules Report as Citi Keeps Sell and $25 Target

HIMS rebounded on Friday, Oct 9, 2026, after a Washington Post report, citing two people familiar with the matter, that federal health officials are working on interim rules allowing certain previously restricted peptides to be sold while permanent regulations are finalized, according to Investing.com. Investing.com had the shares up 7.36% at $30.13 during the session. Yahoo Finance price history shows a close of $30.92, up 10.19% from Thursday's $28.06, after a high of $31.45.

The gain more than erased Thursday's decline, leaving the stock above its Oct 7 close of $29.54. Investing.com put that drop at 5.3%, while Yahoo Finance closes show a 5.0% fall to $28.06; the gap likely reflects different snapshot times. Investing.com also noted that volume of about 7.24 million shares at the time of writing trailed the roughly 12 million three-month average, suggesting the rally lacked broad participation.

Options traders leaned bullish the same day. A TipRanks note said call contracts outnumbered puts, and a TheFly alert carried on TipRanks described moderately bullish activity with the shares up 7.5%. Neither item gives call or put volumes, and neither shows the options activity drove the stock; the reported catalyst was the peptide policy report.

Analysts remain cautious. Citi rates the stock Sell with a $25 target, the most bearish stance among major brokers per Investing.com; its headline's 17% downside is that target measured against the $30.13 intraday price. Truist reiterated Hold with a $32 target on Oct 8, and the consensus across 16 brokerages is Hold with an average target of $32.50. TipRanks flags high debt, shrinking margins and regulatory overhangs, with the stock down 13.58% year to date.

The next catalyst is third-quarter earnings on Nov 9. Investors may watch whether interim peptide rules are formalized, and Hims & Hers' plans to offer sermorelin, glutathione and NAD+ by the end of 2026; BPC-157 depends on formal FDA action.